Researchers from the University of California-Los Angeles say that a drug approved for treating melanoma has shown promise for the treatment of advanced nonsmall cell lung cancer.

Nonsmall cell lung cancer (NSCLC) is the most common form of lung cancer in the US, accounting for around 85-90% of cases and for patients with advanced NSCLC, the treatment outcomes are poor.

However according to lead study author Dr. Edward Garon, of the Jonsson Comprehensive Cancer Center at UCLA, an immunotherapy drug called pembrolizumab has demonstrated effectiveness for reducing tumour progression in patients with advanced NSCLC.

To read the story in full, click here- http://www.medicalnewstoday.com/articles/292589.php